Omalizumab (Xolair) Pharmacokinetic ELISA
Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds human immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU) . Omalizumab inhibits the binding of IgE to IgE receptor (FcεRI) on the surface of mast cells and basophils thereby limiting the release of mediators of the allergic response from the FcεRI bearing cells.
Product Specifications
CAS Number
7732-18-5
Gene ID
3497
Reactivity
Human, mouse, rat
Reaction Volume
15 µL
Target Antigen
Omalizumab (Xolair)
Detection Method
Peroxidase / OD450
Assay Type
ELISA
Assay Principle
Quantification of Omalizumab in biological matrices
Assay Protocol
Assay Performance Time
2.5 hours
Sample Type
Serum Plasma
Sample Volume
15ul
Detection Range
50ng/ml - 1.56ng/ml
Precision
<10%, <10%
Sensitivity
Omalizumab
Limit Of Detection
1.5ng/ml
Components
Shipping Conditions
Blue Ice
Storage Conditions
-20C, 1 year
Shelf Life
12 months
Specificity
Omalizumab
Method
Direct sandwich ELISA
Preservative
None
Preparation
Operating Procedure
Results Calculation
Sample Collection
This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20°C for up to 1 year.
Sample Preparation
Plate
Strip
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items